



Independent observer
of the Global Fund

A BREAKDOWN OF THE ROUND 2 GRANTS

The following data are obtained primarily from a Secretariat paper to the Board entitled “Report of the Secretariat and the Technical Review Panel on Round 2 Proposals” (Revision 1) and a Secretariat slide show entitled “Summary of Key Findings from Round Two”, both dated January 2003.

Regional split of proposals received in Round 2:

(in dollars to be spent over 5 years; 100% = \$5.1 b.)

Africa: . . 58% S.E. Asia: . 12% Americas: . . 13% Eastern Med. 6% Europe: . . . 5% West Pacific 5% Global:

Disease component split of proposals received in Round 2:

(in dollars to be spent over 5 years; 100% = \$5.1 b.)

HIV/AIDS: . 59% Malaria: . . 23% TB: 11% HIV/TB: . . 7% Integrated: 1%

Source of application of proposals received in Round 2:

(in dollars to be spent over 5 years; 100% = \$5.1 b.)

CCM: 89% Regional org: 6% NGO: 3% Sub CCM: . . 2% Regional CCM: 1% Other: . . . 1%

Outcome of the review process:

(in dollars to be spent over 5 years; 100% = \$5.1 b.)

Approved (Category 1): 4% Approved (Category 2): 35% Rejected (Category 3): 55% Rejected (Category 4):

Definitions:

- Approved (Category 1): Approved proposal requiring no or minor modifications, which should easily be answered within 6 weeks and given the final approval by the TRP Chair and Co-Chair.
- Approved (Category 2): Approved proposal provided clarifications are met within a limited timeframe (6 weeks for the applicant to respond, at most 6 months to obtain the final TRP approval should further clarifications be requested). The primary reviewer, secondary reviewer as well as TRP Chair and/or Co-Chair need to give final approval.
- Rejected (Category 3): Not recommended in its present form but strongly encouraged to re-submit.
- Rejected (Category 4): Not recommended for funding.

Cost of approved proposals:

Year 1: \$430 m. Years 1-2: \$866 m. Years 1-3: \$1,276 m. Years 1-4: \$1,651 m. Years 1-5: \$2,051 m.

Regional split of proposals approved in Round 2:

(in dollars to be spent over 2 years; 100% = \$866 m.)

Africa: . . 61% S.E. Asia: . 9% Americas: . 9% Eastern Med. 8% Europe: . . 9% West Pacific 4%

Disease component split of proposals approved in Round 2:

(in dollars to be spent over 2 years; 100% = \$866 m.)

HIV/AIDS: . 57% Malaria: . 28% TB: 14% HIV/TB: . . 1% Integrated: 1%

Expenditure split of proposals approved in Round 2:

(in dollars to be spent over 5 years; 100% = \$2,051 m.)

Drugs: 30% Commodities & products: 26% Training & planning: . 11% Human resources: . . . 9%

Distribution split among implementing partners for proposals approved in Round 2:

(in dollars to be spent over 5 years; 100% = \$2,051 m.)

Government: 54% NGO: 23% Faith-based orgs: 18% Private sector

Antiretroviral recipients in developing countries:

Currently: - Sub-Saharan Africa: . . . 50,000 - All other dev. Countries: 250,000 - Total: 300,000

Supported by Round 1 grants, by end of 5 years: - Sub-Saharan Africa: . . . 80,000 - All other dev. Countries:

Supported by Round 2 grants, by end of 5 years: - Sub-Saharan Africa: . . . 190,000 - All other dev. Countries:

Total: - Sub-Saharan Africa: . . . 320,000 - All other dev. Countries: 470,000 - Total: 790,000

Antiretroviral recipients from Round 2 grants by end of 5 years (or earlier, in some cases):

Armenia	30	Benin	2,000	Botswana	20,000	Bulgaria	200	Burkina Faso	
-------------------	----	-----------------	-------	--------------------	--------	--------------------	-----	------------------------	--

Total: 267,756

[Read More](#)
